Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.

ABSTRACT:

Background

Therapeutic options to treat Non-alcoholic steatohepatitis (NASH) are limited. Mineralocorticoid receptor (MR) activation could play a role in hepatic fibrogenesis and its modulation could be beneficial for NASH.

Aim

To investigate whether eplerenone, a specific MR antagonist, ameliorates liver damage in experimental NASH.

Methods

C57bl6 mice were fed a choline-deficient and amino acid-defined (CDAA) diet for 22 weeks with or without eplerenone supplementation. Serum levels of aminotransferases and aldosterone were measured and hepatic steatosis, inflammation and fibrosis scored histologically. Hepatic triglyceride content (HTC) and hepatic mRNA levels of pro-inflammatory pro-fibrotic, oxidative stress-associated genes and of MR were also assessed.

Resul

SUBMITTER: Pizarro M 

PROVIDER: S-EPMC4522413 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature